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Identifying phronotypes in psychiatry
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Refinements in the methods of diagnosis for psychiatric disorders are critically needed. These 
new methods should be based on objectively measured brain characteristics that provide 
clinically useful information. Studying the brain with respect to psychiatric disorders, however, 
faces numerous challenges. Utilizing techniques learned in other areas of medicine to deal with 
symptoms that lead to complex disorders can provide insight into improving diagnostic models 
in psychiatry. Specifically, many areas of medicine use objective measures of an organ’s function 
or characteristic to guide clinical management of particular subjective complaints. In psychiatry, 
an objectively measured brain characteristic that provides clinically useful information is proposed 
to be that person’s “phronotype.” Important requirements to developing phronotypes are 
discussed. Identifying phronotypes in psychiatry will require a specific investigative approach 
that must be grounded in rigorous scientific methodology. Successfully developing such markers 
will have a profound impact on clinical care, clinical research, basic science research, and most 
importantly the lives of those suffering from these illnesses.
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their patients. To improve our outcomes, however, a model of ill-
ness that moves beyond the syndrome level to the level of organ 
dysfunction is needed.
Psychiatry faces a number of significant obstacles to developing 
a diagnostic model based on organ dysfunction. For most of our 
psychiatric illnesses, there are no clear neuropathologic changes 
that are diagnostic even at autopsy. There are numerous reasons 
for this lack of knowledge, but several are important to point out. 
One, the brain is surrounded by bone, skin, and tissues that make 
evaluating the organ very difficult. Two, the function of the brain 
as it relates to psychiatric illnesses cannot be easily assessed like the 
function of the lungs, heart, or kidneys. This is partly related to the 
first point, but more fundamentally by the nature of the functions 
that the brain performs. Three, the brain is not an organ that can 
be ethically biopsied for routine study. Thus, the study of human 
brain tissue is limited to post-mortem or post-operative specimens 
in a very select group of patients. Both types of samples for various 
reasons are limited in what type of questions can be investigated. 
Four, attempts to identify neuropathologic markers have generally 
grouped patients based on syndrome diagnoses and determined 
what is different about the brains (e.g., structure and/or function) 
of a group of patients and some control group. This strategy makes 
the fundamental assumption that patients with similar symptoms 
have a similar disease (i.e., neuropathology). There is a growing 
body of evidence, however, that this is not likely to be the case. 
Also, this method does not allow assessments to be made about 
individuals, only groups of individuals. Five, psychiatric illnesses 
are very complex disorders that result from interactions of genetic, 
epigenetic, developmental, neuronal, environmental, and cultural 
factors. Six, there exists no clear animal models of many of our 
psychiatric diseases that encompass the full illness. Although there 
are animal models used to study psychiatric diseases, these often 
focus on some aspect of the illness that appears to be similar in 
humans and animals. Whether the neuropathology that result in 
There is a critical need for new methods to diagnose psychiatric ill-
nesses (Insel and Wang, 2009). These new methods must be based on 
disease models that enable clinicians to achieve better outcomes for 
their patients and researchers to develop more effective treatments. 
Thus, the purpose of these models is to improve patient outcome 
and that is how they should be evaluated. Our current model of 
diagnosis involves acquiring a group of signs and symptoms that the 
patient either describes or is observed experiencing. This results in 
a syndrome based diagnosis, but not necessarily an etiological based 
one. Occasionally objective measures such as laboratory testing of 
blood or neuroimaging are acquired, but these tests are only used to 
rule out other causes – not to refine the psychiatric diagnosis. If the 
current method of diagnosis provided a system in which illnesses 
could be effectively identified and treated, further refinement of 
the diagnostic model would not be a critical issue. Unfortunately, 
however, recent large scale studies have demonstrated that even in 
optimal treatment settings, a significant portion of our patients 
do not get better and/or do not stay well (Lieberman et al., 2005; 
Perlis et al., 2006; Rush et al., 2006). Although the current psychi-
atric diagnostic system was an important step in helping psychiatry 
move forward as a medical specialty, new models of these illnesses 
are necessary to advance psychiatric medicine (Nestler et al., 2002; 
Hyman and Fenton, 2003).
Developing a new diagnostic method or system should involve 
building a brain-based model of psychiatric illnesses. All models are 
over simplifications of reality and are thus at some level inaccurate. 
But much like a road map is an over simplification of a system of 
roads, the map is still a very useful tool with which to navigate. In a 
similar manner, brain based models of psychiatric illnesses do not 
necessarily have to capture all of the complexity of the illness in 
order to have value. The crucial question becomes – does the model 
improve the care of the patient? The current model of psychiatric 
illness that categorizes diagnoses by a series of signs and symptoms 
has been reasonably successful at enabling physicians to care for 
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an intermediate “type,” the term endophenotype was coined as an 
intermediate link between observable characteristics and genetics. 
Gottesman and Gould (2003) discuss the endophenotype concept 
for psychiatry in a very nice review. Their criteria for a character-
istic or finding to be an endophenotype include: one, is associated 
with the illness in the population; two, is heritable; three, is state 
independent; four, co-segregates with illness within families; and 
five, is found in a higher percentage of an affected person’s family 
members who do not have the illness than in the general popula-
tion. Thus, the focus of the endophenotype is finding a direct link 
between the genotype and observable behavior and not on defin-
ing a brain function or characteristic. This is in contrast to the 
phronotype, which is only concerned with a brain attribute (e.g., 
function) that provides clinical value. Defining phronotypes of cur-
rent psychiatric diagnoses may or may not relate to the underlying 
genetics of psychiatric disorders, but that would not be their focus 
during development. Future studies could address the relationship 
between phronotypes and genotypes.
Although the distinctions between phronotype and both geno-
type and phenotype are relatively clear, the differentiation of a phe-
notype and endophenotype is less obvious. The concepts are similar 
in that both would be associated with the illness in the population, 
but there are several key differences. The fundamental difference 
is the heritability of the brain marker. For an endophenotype, the 
trait must be heritable, co-segregate with illness within families, and 
appear in unaffected family members at a higher percentage than 
the general population. Conversely, a phronotype is a functional 
measure that is independent of heritability. Using the PFT as an 
example of a functional measure of the lungs, a child with reactive 
airway disease (RAD) who has a PFT result indicative of obstructive 
airway disease may or may not have relatives with a similar result. 
The clinically pertinent point is that the child has the objective 
organ function characteristic that will guide treatment –  regardless 
of whether his RAD was the result of genetic, environmental, or 
some combination of factors. Another important distinction is 
that an endophenotype is state independent (i.e., a trait), while a 
phronotype can be related to either the state or trait – as long as it 
provides clinically relevant information.
A classification system based on phronotypes would have radi-
cal clinical and research implications as well as provide a pathway 
to reach the National Institute of Mental Health’s strategic goal of 
personalized medicine. Following strategies from other areas of 
medicine offers a guide to developing phronotypes in psychiatry. 
As a starting point, testing differences in the function of the organ 
(i.e., the brain) in which the symptoms (e.g., depressive, psychotic, 
anxious symptoms) originate makes the most sense. The testing 
methodology must also be safe, able to be implemented in clinical 
care, and provide reliable information at the individual level. For 
a clinical diagnostic test to be meaningful, it must have validity at 
the individual level (Kozel and Trivedi, 2008). Also, in assessing 
the functional state of an organ, having a measure of the organ in 
a dynamic state generally provides the most sensitive and specific 
diagnostic information. One unique aspect to developing a diag-
nostic test in patients with psychiatric disorders is that the illness 
itself impacts on the patient’s level of effort in performing a test. 
A diagnostic test dealing with psychiatric disorders should ideally 
be independent of the patient’s effort.
the human and animal symptoms are similar is not known – largely 
because we do not have brain based models of psychiatric diseases 
in humans. These above factors have made the development of 
brain-based models of psychiatric illnesses very challenging.
Other areas of medicine (e.g., cardiology, pulmonology) have 
addressed the problem of disease complexity at the symptom level 
(e.g., chest pain, shortness of breath) by measuring the function of 
the organ of interest (e.g., cardiac stress test, pulmonary function 
test – PFT). This enables the diagnoses to be based on organ pathol-
ogy. These etiologic based diagnostic systems provide measures 
that aid in diagnosis, a metric to assess outcome, and a means to 
develop a targeted approach for treatment development. A similar 
approach should be taken with psychiatric diseases.
As an example, take the syndrome of major depressive disorder 
(MDD). Currently, when a patient presents with the complaint of 
depressive symptoms, information is acquired regarding current 
and past symptoms (e.g., problems with mood, sleep, concentra-
tion, appetite, anxiety, mania, psychosis, etc.) and other history (e.g., 
substance use, medical problems, medications, family history, etc.). 
These are put together to make a syndrome diagnosis (e.g., MDD) 
(DSM-IV, 1994). The diagnosis is reliable in that most clinicians 
would make the same diagnosis, and it does provide information 
related to treatment (i.e., a group of patients with similar symptoms 
have been found to be more likely to respond to various antide-
pressant treatments than to placebo treatments). This has enabled 
clinicians to successfully treat a majority of patients with MDD. 
Unfortunately, for a substantial portion of patients suffering with 
MDD, however, their symptoms are not relieved with standard 
treatments. Even for those who eventually do respond, it may take 
multiple treatment trials resulting in prolonged morbidity before 
the successful treatment is chosen. Thus, a better means to categorize 
patients who present with depressive symptoms is needed. Again, 
other areas of medicine have accomplished this by measuring the 
functional output of the organ of interest. Similarly, patients with 
psychiatric diseases could be classified by some brain attribute or 
function. The term “phronotype” is proposed to indicate an objec-
tively measured brain characteristic that provides clinically useful 
information. The term is derived from phon-o- from the Ancient 
Greek phontis1 meaning thought or brain, and type from the Ancient 
Greek typos meaning model or type. Thus, an individual’s objec-
tively measured functional brain output that provided clinically 
relevant information would be that person’s phronotype.
The functional output of the brain as it relates to psychiat-
ric diseases, however, is not easily measured. One measure is the 
observable characteristics of the illness or phenotype. The word is 
derived from the Ancient Greek phainein meaning to display and 
typos meaning model or type (The American Heritage Dictionary, 
1982). In psychiatry, this is generally regarded as the symptoms of 
the illnesses and is thought to be the resulting interaction of the 
person’s genotype and environment. The genotype is defined as 
the genetic constitution of an individual. The term comes from 
the Greek genos meaning race plus typos meaning model or type 
(The American Heritage Dictionary, 1982). In an attempt to define 
1Phrono – Aeschylus uses the word “phrontis” that translated as “brain” in “Aga-
memnon” v. 165. Only the root phron- is used with the addition of one vowel (o) to 
make the connection with the next consonant.
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methods of older technologies for assessing brain function are 
rapidly  progressing. Various investigators have used functional 
neuroimaging measures (Mayberg, 2003; Dougherty and Rauch, 
2007; Phillips et al., 2008; Savitz and Drevets, 2009; Smith and 
Jakobsen, 2009) and electroencephalography (EEG) (Iosifescu, 
2008) to compare responders and non-responders in an attempt 
to identify predictors of treatment response. Using EEG patterns of 
brain activity has shown promise predicting outcome better than 
a syndrome based diagnosis in MDD (Leuchter et al., 2009a,b) 
and attention-deficit/hyperactivity disorder (ADHD) (Hermens 
et al., 2005; Sangal and Sangal, 2006; Arns et al., 2008). Despite the 
elegant work produced, however, we still do not have an objective 
brain test that aids in clinical decision making (i.e., a more effective 
diagnostic model).
Lessons learned from other areas of medicine can provide some 
clues to developing such a diagnostic model based on phronotypes. 
Measuring the organ while it is functioning often provides the most 
sensitive information. For the brain, much like the heart, even dur-
ing the “resting state,” there is considerable activity. Measuring the 
heart during a resting state (e.g., electrocardiogram) can provide 
useful information as well as in an activated state (e.g., cardiac 
stress test). Similarly, functional brain measures can be acquired 
during non-task periods (resting state) or in an “activated state.” 
There are a number of technologies that measure non-task brain 
function including EEG, positron emission tomography (PET), sin-
gle photon emission computed tomography (SPECT), functional 
magnetic resonance imaging (fMRI), and functional near infrared 
spectroscopy (fNIRS). Non-task fMRI sometimes referred to resting 
state fMRI can be used to assess brain function in a number of ways 
including measuring connectivity between regions (Biswal et al., 
1995). These connectivity measures can be compared to likelihood 
of treatment outcome to determine which provides clinically useful 
information. As an example, a recent study has provided prelimi-
nary evidence that connectivity measures acquired from non-task 
fMRI between the dorsal anterior cingulate gyrus and subcallosal 
cortex are correlated with and could predict treatment outcome 
in MDD (F.A. Kozel, personal communication).
Assessing brain function during an activated state requires the 
brain to be activated and a means to measure the functional brain 
changes (e.g., EEG, PET, SPECT, fMRI, fNIRS, etc.). The brain 
can be activated by various means including: one, performing a 
task (e.g., cognitive or emotional paradigms); two, with sensory 
stimulation (e.g., show flashing lights); or three, with direct brain 
stimulation (e.g., transcranial magnetic stimulation). As previously 
mentioned, the problem with tasks in psychiatric disorders is that a 
hallmark of many of our syndromes is the impact on the patient’s 
level of effort. Thus, specific tasks have the potential confound 
of effort that can be difficult to tease apart from changes due to 
pathology. Conversely, peripheral stimulation does not require 
patient effort and produces functional brain changes – but only 
in specific regions of the brain. These primary sensory regions of 
the brain are, however, not likely to be helpful in developing psy-
chiatric phronotypes. In order to stimulate specific portions of the 
brain without patient effort, direct brain stimulation is required. 
An example of a technology that can safely stimulate the brain is 
transcranial magnetic stimulation (TMS) (George and Belmaker, 
2007). TMS involves using rapidly alternating current in a coil to 
Developing a diagnostic brain test to define phronotypes 
requires a specific approach. Most studies assessing brain func-
tion as it relates to psychiatric syndromes compare a group of peo-
ple with a particular diagnosis and some control group – usually 
healthy controls. Conversely, to develop a phronotype diagnostic 
system, patients with a particular syndrome would have functional 
brain information acquired and then treated with an intervention. 
Functional brain differences at the individual level that distinguish 
those that had a particular clinical response and those that did not 
are determined. These findings would then need to be tested a priori 
on various independent groups of patients with that particular syn-
drome to determine how accurately the phronotype distinguished 
the patients as responders versus non-responders. The functional 
brain “marker” (if validated) would provide a phronotype diagno-
sis that provided more information on likelihood of response for 
a particular treatment than a purely syndrome based diagnosis. 
This is analogous to a patient presenting with the complaint of 
shortness of breath and a physician ordering a PFT. The result of 
the PFT (e.g., obstructive, restrictive, or normal pattern) enables 
the physician to choose a treatment or obtain additional testing to 
refine the diagnosis even further. Similarly, a patient with depres-
sive symptoms could undergo a test of brain function that has been 
validated to predict clinical outcome. Depending on the result, a 
treatment would be chosen or further testing order. Thus, the focus 
of developing the phronotype is not to distinguish syndrome ver-
sus health, but to provide information regarding treatment choice 
within a syndrome (see Figure 1).
Developing phronotypes requires a safe and reliable method 
to measure brain function. Although the brain is not an easily 
accessed organ, functional measures of brain activity have been 
developed. This has led to an explosion of research investigating 
the brain – especially as it relates to psychiatric disorders. New 
methods of imaging the brain as well as developing new  analysis 
Figure 1 | Outlines the role that phronotypes will play in the 
management of psychiatric disorders. As a simplified example, the 
symptoms of depression are compared with the symptoms of shortness of 
breath. For depressive symptoms (Depression), there currently exists no 
object test that can refine diagnosis to improve outcome. Conversely, the 
symptom of shortness of breath can be better characterized with a pulmonary 
function test (PFT). The results of the PFT enable the physician to more 
effectively target treatments and/or further evaluation.
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progress from a diagnostic nomenclature that uses terms that have 
become non-specific in common usage (e.g., depressed,  manic, 
panic, anxious, and schizophrenic – often incorrectly used for 
 dissociative identity disorder) to a nomenclature that is precise 
and emphasizes the brain dysfunction in these disorders. Moving 
away from terms that are often used to describe normal variations 
in emotion or behavior will help emphasize that these conditions 
are severe medical illnesses. Also, the ability to focus the pathology 
on the brain dysfunction versus the patient could help combat the 
stigma associated with mental illnesses.
In summary, phronotypes are objectively measured brain char-
acteristics that provide clinically useful information. Developing 
phronotypes in psychiatry will require a specific research approach 
that focuses on an individual’s brain attributes and their relation-
ship to clinical outcome. The value of the models being developed 
need to be judged based on empiric results of studies that test 
whether the models provide clinical advantage. These phrono-
types have the potential to improve the lives of people who suf-
fer from psychiatric disorders with respect to many aspects of 
their illness.
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induce magnetic fields. These magnetic fields pass from the coil 
relatively unimpeded to the brain and induce electrical fields that 
can depolarize neurons (e.g., stimulating the thumb area of the 
motor cortex can make the thumb twitch) (Hallett, 2007). When 
TMS is provided repeatedly at a specific frequency, it is referred to 
as repetitive TMS (rTMS). Thus, rTMS is a safe and non-invasive 
technology to activate a focal portion of the cortex that does not 
require any effort on the part of the patient. Combining rTMS 
with a non-invasive functional brain measure offers the promise 
of developing a test to determine phronotypes within psychiatric 
syndromes. Specific portions of the cortex can be non-invasively 
stimulated and functional status measured. In addition, measur-
ing the changes in other areas of the brain during stimulation can 
assess the functional connectivity status of the region being stimu-
lated. Because the functional brain changes induced by rTMS can 
be altered depending on the TMS parameters being chosen (e.g., 
frequency), various aspects of brain inhibitory (e.g., 1 Hz) and 
excitatory (e.g., 10 Hz) function can be assessed in an individual. 
Thus, combining non-invasive brain stimulation with neuroimag-
ing and testing the relationship to clinical outcome offers a means 
to determine which are clinically useful.
Further testing is required to determine if and how these tech-
nologies can better identify which patients are likely to respond to 
a particular treatment (i.e., phronotypes). Combining minimally 
invasive brain stimulation with neuroimaging or using non-task 
fMRI, however, offers the potential to provide research that will 
have direct clinical benefits in the near future. Importantly, these 
are only two examples of a number of different technologies that 
could provide brain measures that could successfully serve as 
phronotypes.
Developing phronotypes in psychiatry – regardless of the tech-
nology to be used – will require a specific scientific approach that 
has a different focus than much of the current research paradigms. 
The focus will be on separating individuals within a syndrome 
versus separating between a syndrome and health. Measures will be 
acquired at the level of the individual patient, and models will be 
empirically tested to determine if they accurately predict treatment 
outcome. In order for a model to have value, it must provide testable 
hypotheses and have some utility. Because we do not currently have 
neuropathologic findings for most psychiatric disorders to guide 
our diagnostic models, treatment outcome (i.e., endpoint upon 
which the model is tested) will need to drive our classification 
system. Having a brain measure that indicates likelihood of treat-
ment response will provide valuable and much needed guidance to 
clinicians as well as help direct future research. Investigators doing 
basic science research can design specific animal models based on 
the objective phronotypes in humans to develop a greater under-
standing of the brain basis of these diseases and test new treat-
ments. In addition, the ability to better categorize patients with 
phronotypes will have other positive consequences. Psychiatry can 
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